{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:13:06Z","timestamp":1760263986300,"version":"build-2065373602"},"reference-count":22,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T00:00:00Z","timestamp":1303776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>A study was undertaken to investigate the prognostic impact of deletions of derivative chromosome 9 in 353 patients with CML receiving the second generation tyrosine kinase inhibitors (TKIs) nilotinib (n = 161) or dasatinib (n = 192).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Deletion of derivative chromosome 9 status was determined in 245 (69%). Twenty\u2010eight (11%) patients, 22 in chronic phase, 4 in accelerated phase, and 2 in blast phase, carried deletions of derivative chromosome 9, including 17 receiving nilotinib and 11 receiving dasatinib (<jats:italic>P<\/jats:italic> = .47). Overall survival (OS) at 24 months was similar between patients with or without deletions of derivative chromosome 9 (70% vs 71%, <jats:italic>P<\/jats:italic> = .76). For patients in chronic phase, no significant differences in overall major cytogenetic response (77% vs 82%, <jats:italic>P<\/jats:italic> = .57) or complete cytogenetic response (77% vs 81%, <jats:italic>P<\/jats:italic> = .71) rates were observed between patients with or without deletions of derivative chromosome 9. At 24 months, patients with CML in chronic phase without deletions of derivative chromosome 9 had improved event\u2010free survival (EFS) (88% vs 66%, <jats:italic>P<\/jats:italic> = .07) and OS (96% vs 82%; <jats:italic>P<\/jats:italic> = .08) compared with those carrying deletions of derivative chromosome 9. However, multivariate analysis established second\u2010line versus frontline second generation TKI therapy as the only adverse prognostic factor for EFS and increased bone marrow blast burden and older age as independent adverse prognostic factors for OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Deletions of derivative chromosome 9 do not appear to be an independent risk factor for survival among patients with CML in chronic phase receiving second generation TKIs. Cancer 2011;. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26147","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T17:08:45Z","timestamp":1303837725000},"page":"5085-5093","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib"],"prefix":"10.1002","volume":"117","author":[{"given":"Alfonso","family":"Quint\u00e1s\u2010Cardama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne V.","family":"Abruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144790"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V81.1.158.158","article-title":"The ABL\u2010BCR fusion gene is expressed in chronic myeloid leukemia","volume":"81","author":"Melo JV","year":"1993","journal-title":"Blood."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2879"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1732"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.3.738.003k21_738_743"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2208"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0123"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2763"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23607"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3581"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074252"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7963"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.181.181","article-title":"High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph\u2010positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]","volume":"112","author":"Rosti G","year":"2008","journal-title":"Blood."},{"key":"e_1_2_7_17_2","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML\u2010CP) [abstract]","volume":"112","author":"Cortes J","year":"2008","journal-title":"Blood."},{"key":"e_1_2_7_18_2","article-title":"Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)\u2010positive chronic myelogenous leukemia in early chronic phase (CML\u2010CP) [abstract]","volume":"112","author":"Cortes J","year":"2008","journal-title":"Blood."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4547"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00350.x"},{"key":"e_1_2_7_23_2","first-page":"952","article-title":"Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia","volume":"91","author":"Fourouclas N","year":"2006","journal-title":"Haematologica."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26147","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:34:39Z","timestamp":1760261679000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,26]]},"references-count":22,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2011,11,15]]}},"alternative-id":["10.1002\/cncr.26147"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26147","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2011,4,26]]}}}